JP2022513001A - Ｂ型肝炎の治療のための免疫原性組成物 - Google Patents

Ｂ型肝炎の治療のための免疫原性組成物 Download PDF

Info

Publication number
JP2022513001A
JP2022513001A JP2021525603A JP2021525603A JP2022513001A JP 2022513001 A JP2022513001 A JP 2022513001A JP 2021525603 A JP2021525603 A JP 2021525603A JP 2021525603 A JP2021525603 A JP 2021525603A JP 2022513001 A JP2022513001 A JP 2022513001A
Authority
JP
Japan
Prior art keywords
hepatitis
hbsag
antigen
aluminum
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513001A5 (https=
Inventor
デビッド， エヴァンダー アンダーソン，
タンヴィール アハメド，
Original Assignee
ヴァリエーション バイオテクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァリエーション バイオテクノロジーズ インコーポレイテッド filed Critical ヴァリエーション バイオテクノロジーズ インコーポレイテッド
Publication of JP2022513001A publication Critical patent/JP2022513001A/ja
Publication of JP2022513001A5 publication Critical patent/JP2022513001A5/ja
Priority to JP2024157339A priority Critical patent/JP2024174990A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021525603A 2018-11-13 2019-11-13 Ｂ型肝炎の治療のための免疫原性組成物 Pending JP2022513001A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024157339A JP2024174990A (ja) 2018-11-13 2024-09-11 Ｂ型肝炎の治療のための免疫原性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760439P 2018-11-13 2018-11-13
US62/760,439 2018-11-13
PCT/IB2019/001230 WO2020099927A1 (en) 2018-11-13 2019-11-13 Immunogenic compositions for treatment of hepatitis b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024157339A Division JP2024174990A (ja) 2018-11-13 2024-09-11 Ｂ型肝炎の治療のための免疫原性組成物

Publications (2)

Publication Number Publication Date
JP2022513001A true JP2022513001A (ja) 2022-02-07
JP2022513001A5 JP2022513001A5 (https=) 2022-10-28

Family

ID=70731781

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525603A Pending JP2022513001A (ja) 2018-11-13 2019-11-13 Ｂ型肝炎の治療のための免疫原性組成物
JP2024157339A Pending JP2024174990A (ja) 2018-11-13 2024-09-11 Ｂ型肝炎の治療のための免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024157339A Pending JP2024174990A (ja) 2018-11-13 2024-09-11 Ｂ型肝炎の治療のための免疫原性組成物

Country Status (10)

Country Link
US (2) US12128100B2 (https=)
EP (1) EP3880244A4 (https=)
JP (2) JP2022513001A (https=)
KR (1) KR102943479B1 (https=)
CN (2) CN118987191A (https=)
BR (1) BR112021009234A2 (https=)
IL (2) IL314712A (https=)
MX (1) MX2021005588A (https=)
WO (1) WO2020099927A1 (https=)
ZA (1) ZA202103976B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024174990A (ja) * 2018-11-13 2024-12-17 ヴァリエーション バイオテクノロジーズ インコーポレイテッド Ｂ型肝炎の治療のための免疫原性組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240123060A1 (en) * 2019-06-21 2024-04-18 Variation Biotechnologies Inc. Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b
AU2024313135A1 (en) 2023-06-23 2026-01-22 Brii Biosciences, Inc. Assessment and treatment of chronic hepatitis b

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010209118A (ja) * 1998-05-01 2010-09-24 Glaxosmithkline Biologicals Sa 新規組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242812A (en) 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
CN1305527C (zh) 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CN102949717A (zh) 2012-07-06 2013-03-06 中国疾病预防控制中心病毒病预防控制所 一种含poly I:C佐剂的新型乙肝疫苗制剂
CN104043120B (zh) 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 乙型肝炎疫苗
WO2018166298A1 (en) 2017-03-13 2018-09-20 Fudan University Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
WO2020099927A1 (en) * 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b
US20240123060A1 (en) 2019-06-21 2024-04-18 Variation Biotechnologies Inc. Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010209118A (ja) * 1998-05-01 2010-09-24 Glaxosmithkline Biologicals Sa 新規組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
IMAJ, vol. 3, JPN6023037225, 2001, pages 328 - 332, ISSN: 0005432112 *
MED MICROBIOL IMMUNOL, vol. 204, JPN6023037224, 2015, pages 57 - 68, ISSN: 0005432113 *
VACCINE, vol. 18, JPN6024009198, 2000, pages 1227 - 1235, ISSN: 0005280724 *
VACCINE, vol. 25, JPN6023037221, 2007, pages 6618 - 6624, ISSN: 0005432116 *
VACCINE, vol. 27, JPN6023037222, 2009, pages 888 - 892, ISSN: 0005432115 *
VACCINE, vol. 27, JPN6023037223, 2009, pages 3175 - 3180, ISSN: 0005432114 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024174990A (ja) * 2018-11-13 2024-12-17 ヴァリエーション バイオテクノロジーズ インコーポレイテッド Ｂ型肝炎の治療のための免疫原性組成物

Also Published As

Publication number Publication date
US20250269013A1 (en) 2025-08-28
EP3880244A1 (en) 2021-09-22
KR102943479B1 (ko) 2026-03-27
ZA202103976B (en) 2023-09-27
CA3119581A1 (en) 2020-05-22
KR20210151047A (ko) 2021-12-13
BR112021009234A2 (pt) 2021-09-08
US12128100B2 (en) 2024-10-29
IL283039B1 (en) 2024-09-01
JP2024174990A (ja) 2024-12-17
CN113423423A (zh) 2021-09-21
MX2021005588A (es) 2021-08-11
IL283039A (en) 2021-06-30
WO2020099927A1 (en) 2020-05-22
EP3880244A4 (en) 2022-08-17
US20230079703A1 (en) 2023-03-16
IL283039B2 (en) 2025-01-01
IL314712A (en) 2024-10-01
CN113423423B (zh) 2024-08-13
CN118987191A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
JP5814507B2 (ja) ワクチン
RU2160120C2 (ru) Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
JP6499592B2 (ja) Ｂ型肝炎ワクチン
JP2024174990A (ja) Ｂ型肝炎の治療のための免疫原性組成物
JP7779837B2 (ja) 医薬組成物及びその用途
JPH085804B2 (ja) Ａ型及びｂ型肝炎混合アジュバントワクチン
JPH07505372A (ja) ３−ｏ−脱アシル化モノホスホリル脂質ａ含有の肝炎ワクチン
CN110944662A (zh) 用于治疗和/或预防hbv感染的组合物及其用途
CN104873969B (zh) 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗
EP3986459A1 (en) Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b
CN108567977A (zh) 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
CA3119581C (en) Immunogenic compositions for treatment of hepatitis b
CN107693788B (zh) 一种用于预防或治疗乙型肝炎的药物组合物及其用途
HK40050381A (en) Immunogenic compositions for treatment of hepatitis b
HK40050381B (zh) 用於治疗乙型肝炎的免疫原性组合物
KR102743672B1 (ko) 점막에서 항원 특이적 면역 반응을 증진시키는 신규한 펩타이드 및 상기 펩타이드를 유효성분으로 포함하는 점막 백신 보조제
WO2023240278A2 (en) Uses of glycolipids as a vaccine adjuvant and methods thereof
HK40062132A (en) Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b.
HK40015475A (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
EA040981B1 (ru) Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008